Researchers address the meaning of the genomic revolution
12 October, 2005 by Graeme O'NeillGenetics genomics have disturbed science's dreams of explaining human nature and individuality as merely a function of the activity of genes, modulated by environmental factors, according to University of Queensland Federation Fellow Professor Paul Griffiths.
ChemGenex pinpoints inflammation gene
10 October, 2005 by Graeme O'NeillDiabetes- and oncology-gene hunter ChemGenex Pharmaceuticals (ASX:CXS) now has solid evidence that a particular variant of the SEPS-1 gene, already identified as a trigger for Type 2 diabetes, is a strong risk factor for a broad range of chronic inflammatory disorders.
Mimotopes to produce peptides for Invitrogen
06 October, 2005 by Ruth BeranMimotopes, a wholly owned subsidiary of PharmAust (ASX:PAA), is to supply California-based life science technology group Invitrogen Corporation (NASDAQ:IVGN) with custom pre-clinical peptides for Invitrogen's customers worldwide.
Opinion: Why we're backing off from biotech
19 September, 2005 by Peter BickDump the drugs? No -- but dump the stigma of 'biotech' and look for proper recognition from the investment community, writes CogState CEO Peter Bick.
CSIRO wins US patent for key RNAi vector
13 September, 2005 by Graeme O'NeillThe legal mists swirling the issue of ownership of key patents to RNA-induced (RNAi) gene silencing are lifting, with the US Patent Office granting CSIRO a patent for its Hellsgate family of vectors for exploring and manipulating gene function in plants and animals.
Proteome 'scavenger compounds' net US$20 government grant
07 September, 2005 by Helen SchullerA US$20 million grant to develop Proteome Systems' (ASX:PXL) proprietary therapeutic compounds for the treatment of radiation exposure caused by terrorist attacks or industry accidents has been awarded to a consortium comprising Proteome Systems, the Medical College of Wisconsin, Henry Ford Health Systems in Detroit, and the University of Toronto.
Melbourne medical informatics group nets $4.4m in grant round
02 September, 2005 by Ruth BeranThe Bio21 Molecular Medicine Informatics Model (Bio21:MMIM) is one of nine projects to share $19.4 million in recent funding from the Australian government under the Systemic Infrastructure Initiative (SII).
NSW biotech to get 2020 vision at conference
30 August, 2005 by Iain ScottThe scene: biotechnology is the quintessential knowledge-based industry. But most of its advances have come from advancements in information technology, and how they are applied to genetic processes. Could this be a model for the biotechnology industry in NSW in 2020?
Bioinformatics peak body committee elected
11 August, 2005 by Iain ScottBioinformatics Australia, Australia's peak body for bioinformatics, hosted by industry organisation AusBiotech, has announced its newly elected committee.
Aussies asked to apply for UK biotech trade mission
11 August, 2005 by Ruth BeranA trade mission to World Life Sciences Week being held in London this October is taking applications from Australian biotech companies.
Qld team on the pulse of migraine genetics
09 August, 2005 by Graeme O'NeillWhat causes those headaches that keep on thumping after you've exceeded your recommended daily allowance of garden-variety analgesics? A team at QIMR is close to finding out.
Resonance to provide FerriScan to Novartis Pharma
05 August, 2005 by Ruth BeranResonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT) and formerly known as Inner Vision Biometrics, has agreed to provide its FerriScan diagnostic test to Swiss pharmaceutical company Novartis Pharma for use in its clinical studies.
Apollo adds proteins
01 August, 2005 by Graeme O'NeillNewly listed Sydney biopharma Apollo (ASX:AOP) has added another 10 more human-expressed proteins (HEPs) to its library, bringing its portfolio of provisionally patented proteins to 60.
UQ discovers fear protein
19 July, 2005 by Graeme O'NeillResearchers at the University of Queensland's Brain Research Institute have identified a protein expressed in the amygdala, a region of the brain that mediates the formation of fearful memories, that could be a target for new drugs to treat anxiety, panic attacks, phobias and some mental disorders.
Scientists must stand up on cloning: Boswell
06 July, 2005 by Ruth BeranThe National Party's leader in the senate, Senator Ron Boswell, has urged scientists to make submissions to the independent committee appointed to review federal laws restricting stem cell research in Australia.
